| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Topic in appraisal. |
| Process | Cost Comparison Standard |
| ID number | 6336 |
Project Team
| Project lead | Jeremy Powell |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | AstraZeneca (olaparib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Breast Cancer Now |
| MET UP UK | |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| UK Breast Cancer Group | |
| Comparator companies | Pfizer (talazoparib) (CAU signed - participating) |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 August 2024 | We are pausing this appraisal for operational reasons. We will provide a further update when we restart the appraisal. |
| 02 May 2024 | Invitation to participate |
| 08 April 2024 - 22 April 2024 | Review proposal consultation |
| 15 February 2024 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual